Role of PARylation and PTEN Mutation on PARP and PARG Inhibitor Efficacy on Glioblastoma
H. Hermanowski, B. Huebert, C. Aldrighetti, J. K. Hurley, D. Quenet
This study examines the efficacy of PARP and PARG inhibitors in glioblastoma cells with wildtype or mutant PTEN, finding no evidence of synthetic lethality in the absence of other DNA damaging agents.
bioRxiv · Jun 30, 2020 · PreprintCancer Biology